1. Search Result
Search Result
Results for "

unstable angina

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-114603

    LY 294468

    Thrombin Cardiovascular Disease
    Efegatran (LY 294468) is an inhibitor for thrombin, which inhibits aggregation of platelets, and exhibits anticoagulant and antithrombotic activities .
    Efegatran
  • HY-114603A

    LY 294468 sulfate

    Thrombin Cardiovascular Disease
    Efegatran (LY 294468) sulfate is an inhibitor for thrombin, which inhibits aggregation of platelets, and exhibits anticoagulant and antithrombotic activities .
    Efegatran sulfate
  • HY-114603B

    LY 294468 dihydrochloride

    Thrombin Cardiovascular Disease
    Efegatran (LY 294468) dihydrochloride is an inhibitor for thrombin, which inhibits aggregation of platelets, and exhibits anticoagulant and antithrombotic activities .
    Efegatran di(hydrochloride)
  • HY-106904

    Calcium Channel 5-HT Receptor Dopamine Receptor Cardiovascular Disease
    Nexopamil is a calcium antagonist of Ca 2+ channel, 5HT2, 5HT1A, 5HT1C and dopamine D2 receptors. Nexopamil exhibits vasodilatory, cardioprotective, and platelet aggregation inhibiting effects. Nexopamil can be used for researches of stable or unstable angina and possibly of peripheral arterial occlusive disease .
    Nexopamil
  • HY-14654B

    Acetylsalicylic acid DL-lysine; ASA DL-lysine

    COX NF-κB p38 MAPK Cardiovascular Disease Others Inflammation/Immunology
    Aspirin DL-lysine (ASA DL-lysine) is a lysine-containing aspirin derivative. Aspirin DL-lysine inhibits cyclooxygenase (COX) in platelets, blocks the synthesis of thromboxane A2 (TXA2), and thus inhibits platelet aggregation and activation. Aspirin DL-lysine can be used to study thrombin generation in patients with unstable angina pectoris .
    Aspirin DL-lysine
  • HY-10313

    Integrin Cardiovascular Disease
    ZD 2486 is a glycoprotein IIb/IIIa (GP IIb/IIIa) antagonist. ZD 2486 inhibits platelet aggregation by blocking the binding of fibrinogen to the GP IIb/IIIa receptor on platelets. ZD 2486 can be used for the study of conditions related to unwanted platelet aggregation, such as acute coronary syndrome, unstable angina pectoris, acute myocardial infarction, and complications from cardiovascular interventional procedures [1]
    ZD 2486

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: